文献速递心脑血管急症

心血管疾病中阿司匹林剂量的比较有效性

Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
PubMed 文献 · N Engl J Med · 2021-05-15
一句话结论在已确诊动脉粥样硬化性心血管疾病患者中,每日81 mg与325 mg阿司匹林在心血管事件和主要出血方面无显著差异。

本研究为开放标签、实用性设计随机对照试验,纳入15,076例已确诊动脉粥样硬化性心血管疾病患者,随机分配至每日81 mg或325 mg阿司匹林策略。主要有效性终点为全因死亡、心肌梗死住院或卒中住院的复合终点,主要安全性终点为主要出血住院。中位随访26.2个月,81 mg组与325 mg组主要有效性终点发生率分别为7.28%与7.51%(HR 1.02;95%CI 0.91-1.14),主要出血住院发生率分别为0.63%与0.60%(HR 1.18;95%CI 0.79-1.77),均无显著差异。325 mg组剂量转换率更高(41.6% vs 7.1%),中位暴露天数更少(434天 vs 650天)。

要点

  • 在已确诊动脉粥样硬化性心血管疾病患者中,每日81 mg与325 mg阿司匹林的主要有效性复合终点(全因死亡、心肌梗死住院或卒中住院)发生率无显著差异(7.28% vs 7.51%;HR 1.02;95%CI 0.91-1.14)。
  • 主要出血住院发生率在81 mg组与325 mg组间无显著差异(0.63% vs 0.60%;HR 1.18;95%CI 0.79-1.77)。
  • 325 mg组剂量转换率显著高于81 mg组(41.6% vs 7.1%),且中位暴露天数更少(434天 vs 650天)。
  • 随机分组前,96.0%的患者已在服用阿司匹林,其中85.3%每日服用81 mg。

适用人群与场景

  • 已确诊动脉粥样硬化性心血管疾病患者。

处置流程与药物剂量

  • 每日81 mg或325 mg阿司匹林,开放标签、实用性设计。

研究设计与关键结果

  • 研究类型:开放标签、实用性随机对照试验;样本量15,076例;随访中位26.2个月(IQR 19.0-34.9)。
  • 主要有效性终点(全因死亡、心肌梗死住院或卒中住院):81 mg组590例(估计百分比7.28%)vs 325 mg组569例(估计百分比7.51%),HR 1.02;95%CI 0.91-1.14。
  • 主要安全性终点(主要出血住院):81 mg组53例(估计百分比0.63%)vs 325 mg组44例(估计百分比0.60%),HR 1.18;95%CI 0.79-1.77。
  • 325 mg组剂量转换率41.6% vs 81 mg组7.1%;325 mg组中位暴露天数434天(IQR 139-737)vs 81 mg组650天(IQR 415-922)。
  • 随机分组前,13,537例(96.0%有既往阿司匹林使用信息的患者)已在服用阿司匹林,其中85.3%每日服用81 mg。

证据类型、等级与局限

  • 证据类型:开放标签、实用性随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在已确诊动脉粥样硬化性心血管疾病患者中,每日81 mg与325 mg阿司匹林在心血管事件和主要出血方面无显著差异,但325 mg组剂量转换更频繁、暴露天数更少。

指南或共识出处

  • ADAPTABLE试验,ClinicalTrials.gov注册号NCT02697916,由Patient-Centered Outcomes Research Institute资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.

METHODS: Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis. The primary safety outcome was hospitalization for major bleeding, also assessed in a time-to-event analysis.

RESULTS: A total of 15,076 patients were followed for a median of 26.2 months (interquartile range [IQR], 19.0 to 34.9). Before randomization, 13,537 (96.0% of those with available information on previous aspirin use) were already taking aspirin, and 85.3% of these patients were previously taking 81 mg of daily aspirin. Death, hospitalization for myocardial infarction, or hospitalization for stroke occurred in 590 patients (estimated percentage, 7.28%) in the 81-mg group and 569 patients (estimated percentage, 7.51%) in the 325-mg group (hazard ratio, 1.02; 95% confidence interval [CI], 0.91 to 1.14). Hospitalization for major bleeding occurred in 53 patients (estimated percentage, 0.63%) in the 81-mg group and 44 patients (estimated percentage, 0.60%) in the 325-mg group (hazard ratio, 1.18; 95% CI, 0.79 to 1.77). Patients assigned to 325 mg had a higher incidence of dose switching than those assigned to 81 mg (41.6% vs. 7.1%) and fewer median days of exposure to the assigned dose (434 days [IQR, 139 to 737] vs. 650 days [IQR, 415 to 922]).

CONCLUSIONS: In this pragmatic trial involving patients with established cardiovascular disease, there was substantial dose switching to 81 mg of daily aspirin and no significant differences in cardiovascular events or major bleeding between patients assigned to 81 mg and those assigned to 325 mg of aspirin daily. (Funded by the Patient-Centered Outcomes Research Institute; ADAPTABLE ClinicalTrials.gov number, NCT02697916.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021. PMID: 33999548. doi:10.1056/NEJMoa2102137

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。